source
- Werewolf Therapeutics merges with Ambros in $150M deal to advance non‑opioid painkiller for rare limb injury syndromeWerewolf Therapeutics and Ambros Therapeutics announced a merger valued at $150 million, creating a new company that will retain the Ambros name. The deal includes a private placement to fund the…
- Study suggests cancer patients may be receiving higher doses and longer treatment courses than neededRecent analysis highlighted that many cancer patients are being treated with larger drug doses and extended therapy durations than may be medically necessary. The pattern raises concerns about unn…